Role of radiotherapy and hyperthermia in the management of malignant melanoma

Seminars in Surgical Oncology

Volumn 12, Issue 6, 1996, Pages 407-415

  Schmidt Ullrich, Rupert K ^a,b   Johnson, Christopher R ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

combined modality therapy; dose response relationship; induced hyperthermia; local neoplasm recurrence; lymphatic metastasis; melanoma radiotherapy; radiation; radiation tolerance; radiotherapy dosage; remission induction; treatment outcome

Indexed keywords

CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RESISTANCE; DOSE RESPONSE; HUMAN; HYPERTHERMIC THERAPY; LYMPH NODE METASTASIS; MELANOMA; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIVITY; RADIOSENSITIZATION; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; HYPERTHERMIA, INDUCED; LYMPHATIC METASTASIS; MELANOMA; NEOPLASM RECURRENCE, LOCAL; PALLIATIVE CARE; RADIATION TOLERANCE; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 0029832333     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(199611/12)12:6<407::AID-SSU6>3.0.CO;2-E     Document Type: Review

References (66)

1. Miescher G: Zur Frage der Strahlenresistenz der Melanome. Schweiz Med Wochenschr 56:788-812, 1926.
2. Bentzen SM, Overgaard J, Thames HD, et al: Clinical radiobiology of malignant melanoma. Radiother Oncol 16:169-182, 1989.
3. Trott KR: The optimal radiation dose per fraction for the treatment of malignant melanomas. Int J Radiat Oncol Biol Phys 20:905-907, 1991.
4. Barranco SC, Romsdahl MM, Humphrey RM: The radiation response of human malignant melanoma cells grown in vitro. Cancer Res 31:830-833, 1971.
5. Dewey DL: The radiosensitivity of melanoma cells in culture. Br J Radiol 44:816-817, 1971.
6. Rofstad EK: Radiation biology of malignant melanoma. Acta Radiol 25:1-10, 1986.
7. Fowler JF: The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 62:679-694, 1989.
8. Thames HD, Bentzen SM, Turesson I, et al: Time-dose factor in radiotherapy: A review of the human data. Radiother Oncol 19:219-235, 1990.
9. Radford I: Evidence for a general relationship between the induced level of DNA double-strand breakage and cell killing after x-irradiation of mammalian cells. Int J Radiat Biol 49:611-621, 1986.
10. Little JB, Hahn GM, Frindel E, Tubiana M: Repair of potentially lethal radiation damage in vitro and in vivo. Radiology 106:686-694, 1973.
11. Elkind MM, Sutton-Gibert H, Moses WB, et al: Radiation response of mammalian cells in culture: V. Temperature dependence of the repair of x-ray damage in surviving cells (aerobic and hypoxic). Radiat Res 25:359-376, 1965.
12. 3H thymidine incorporation and soft agar clonogenic assays. Eur J Cancer 9:1370-1376, 1994.
13. McKay MJ, Kefford RF: The spectrum of in vitro radiosensitivity in four human melanoma cell lines is not accounted for by differential induction or rejoining of DNA double strand breaks. Int J Radiat Oncol Biol Phys 31:345-352, 1995.
14. Zaffaroni N, Orlandi L, Villa R, et al: DNA double-strand break repair and radiation response in human tumour primary cultures. Int J Radiat Biol 3:279-285, 1994.
15. Courdi A, Bensadoun RJ, Gioanni J, Caldani C: Inherent radiosensitivity and split-dose recovery in plateau-phase cultures of 10 human tumour cell lines. Radiother Oncol 24:102-107, 1992.
16. Lin HS: Adaptation and cross-resistance: An explanation for the existence of different radiosensitivities among malignant melanoma cells. Med Hypotheses 44:73-76, 1995.
17. Overgaard J: The role of radiotherapy in recurrent and metastatic malignant melanoma: A clinical radiobiological study. Int J Radiat Oncol Biol Phys 12:867-872, 1986.
18. Trott KR, von Lieven H, Kummermehr J, et al: Radiosensitivity of melanomas. Part II: Clinical studies. Int J Radiat Oncol Biol Phys 7:15-20, 1981.
19. Ellis F: Nominal standard dose and the ret. Br J Radiol 44:101-108, 1971.
20. Roizin-Towle L, Pirro JP: The response of human and rodent cells to hyperthermia. Int J Radiat Oncol Biol Phys 20:751-756, 1991.
21. Bichay TJ, Feeley MM, Raaphorst GP: A comparison of heat sensitivity, radiosensitivity and PLDR in four human melanoma cell lines. Melanoma Res 2:63-69, 1991.
22. Dewey WC, Hopwood LE, Sapareto LA, Gerweck LE: Cellular responses to combinations of hyperthermia and radiation. Radiology 123:463-474, 1977.
23. Westra A, Dewey WC: Variation in sensitivity to heat shock during the cell cycle of Chinese hamster cells in vitro. Int J Radiat Biol Relat Stud Phys Chem Med 19:467-477, 1971.
24. Gerweck L, Rottinger E: Enhancement of mammalian cell sensitivity to hyperthermia by pH alteration. Radiat Res 67:508-511, 1976.
25. Raaphorst GP, Mao JP, Ng CE: Repair of potentially lethal damage: Its inhibition by hyperthermia in two melanoma cell lines with different radio- and heat sensitivities. Melanoma Res 3:351-356, 1993.
26. Raaphorst GP, Mao JP, Ng CE: Sublethal radiation damage repair and its inhibition by hyperthermia in two human melanoma cell lines of different radiosensitivities. Melanoma Res 4:157-161, 1994
27. Overgaard J: Radiation treatment of malignant melanoma. Int J Radiat Oncol Biol Phys 6:41-44, 1980.
28. Habermalz HJ, Fischer JJ: Radiation therapy for malignant melanoma: Experience with high individual treatment doses. Cancer 38:2258-2262, 1976.
29. Hornsey S: The relationship between total dose, number of fractions and fraction size in the response of malignant melanoma patients. Br J Radiol 51:905-909, 1978.
30. Hellriegel W: Radiation therapy for primary and metastatic melanoma. Ann N Y Acad Sci 100:131-140, 1963.
31. Pyrhönen SO, Kajanti MJ: The use of large fractions in radiotherapy for malignant melanoma. Radiother Oncol 24:195-197, 1992.
32. Habeshaw T, Wheldon TE: Malignant melanoma: The role of radiotherapy. Clin Oncol 3:571-596, 1984.
33. Trotti A, Peters LJ: Role of radiotherapy in the primary management of mucosal melanoma of the head and neck. Semin Surg Oncol 9:246-250, 1993.
34. Harwood A: Conventional fractionated radiotherapy for 51 patients with lentigo maligna and lentigo maligna melanoma. Int J Radiat Oncol Biol Phys 9:1019-1021, 1983.
35. Iverson K, Robins RE: Mucosal malignant melanomas. Am J Surg 139:660-664, 1980.
36. Gilligan D, Slevin NJ: Radical radiotherapy for 28 cases of mucosal melanoma in the nasal cavity and sinuses. Br J Radiol 64:1147-1150, 1991.
37. Harwood AR, Cummings BJ: Radiotherapy for mucosal melanomas. Int J Radial Oncol Biol Phys 8:1121-1126, 1982.
38. Creagan ET, Cupps RE, Ivins, JC, et al: Adjuvant radiation therapy for regional nodal metastases from malignant melanoma. Cancer 42:2206-2210, 1978.
39. Harwood A, Stringer SP, Million RR: Melanoma of the head and neck. In Million RR, Cassisi NJ (eds): "Management of Head and Neck Cancer: A Multidisciplinary Approach." Philadelphia: Lippincott, 1994, 693-709.
40. Ang KK, Peters LJ, Weber RS, et al: Postoperative radiotherapy for cutaneous melanoma of the head and neck region. Int J Radiat Oncol Biol Phys 30:795-798, 1994.
41. Dougherty M, Kligerman MM: Radiotherapy of melanoma. Cancer Treat Res 65:355-371, 1993.
42. Adam JS, Habeshaw T, Kirk J: Response rate of malignant melanoma to large fraction irradiation. Br J Radiol 55:605-607, 1982.
43. Lobo PA, Liebner EJ, Chao JJ, Kanji AM: Radiotherapy in the management of malignant melanoma. Int J Radiat Oncol Biol Phys 7:21-26, 1981.
44. Sause WT, Cooper JS, Rush S, et al: Fraction size in external beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys 20:429-432, 1991.
45. Overgaard J, von der Maase H., Overgaard M: A randomized study comparing two high-dose per fraction schedules in recurrent or matastatic malignant melanoma. Int J Radiat Oncol Biol Phys 11: 1837-1839, 1985.
46. Konefal JB, Emami B, Pilepich MV: Analysis of dose fractionation in the palliation of metastases from malignant melanoma. Cancer 61:243-246, 1988.
47. Katz HR: The results of different frationation schemes in the palliative irradiation of metastatic melanoma. Int J Radiat Oncol Biol Phys 7:907-911, 1981.
48. Hagen NA, Cirrincione C, Thaler HT, et al: The role of radiation therapy following resection of single brain metastases from melanoma. Neurology 40:158, 1990.
49. Rate WR, Solin LJ, Turrisi AT: Palliative radiotherapy for metastatic malignant melanoma. Brain metastases, bone metastases and spinal cord compression. Int J Radiat Oncol Biol Phys 15:859-864, 1988.
50. Overgaard J, Gonzales D, Hulshof MC, et al: Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. Lancet 345:540-543, 1995.
51. Perez CA, Gillespie B, Pajak T. et al: Quality assurance problems in clinical hyperthermia and their impact on therapeutic outcome: A report by the radiation therapy oncology group. Int J Radiat Oncol Biol Phys 16:551-558, 1989.
52. Perez CA, Pajak T, Emami B, et al: Randomized Phase III study comparing irradiation and hyperthermia with irradiation alone in superficial measurable rumors. Am J Clin Oncol 14:133-141, 1991.
53. Engin K, Leeper DB, Tupchong L, et al: Thermoradiation therapy for superficial malignant tumors. Cancer 72:287-296, 1993.
54. Kapp DS, Barnett TA, Cox RS, et al: Hyperthermia and radiation therapy of local-regional recurrent breast cancer: Prognostic factors for response and local control of diffuse or nodular rumors. Int J Radiat Oncol Biol Phys 20:1147-1164, 1991.
55. Ben-Yosef R, Kapp DS: Prognostic factors in metastatic malignant melanoma treated with combined radiation therapy and hyperthermia. Int J Hyperthermia 9:767-781, 1993.
56. Thompson JF, Lai DT, Ingvar C, Kam PC: Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma. Melanoma Res 4 [Suppl 1]:45-50, 1994.
57. Bowers GJ, Copeland EM: Surgical limb perfusion for extremity melanoma. Surg Oncol 3:91-102, 1994.
58. Coit DG: Hyperthermia isolation limb perfusion for malignant melanoma: A review. Cancer Invest 10:277-284, 1992.
59. Ghussen F, Kruger I, Groth W, Stutzer H: The role of hyperthermic cytostatic perfusion in the treatment of extremity melanoma. Cancer 61:654-659, 1988.
60. Kapteijn BA, Klaase JM, van Geel AN, et al: Results of regional isolated perfusion for locally inoperable melanoma of the limbs. Melanoma Res 4:135-138, 1994.
61. Vaglini M, Belli F, Ammatuna M, et al: Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose alpha-tumor necrosis factor, gamma-interferon, and melphalan. Cancer 73:483-492, 1993.
62. Klaase JM, Kroon BB, van Geel BN, et al: Patient- and treatment-related factors associated with acute regional toxicity after isolated perfusion for melanoma of the extremities. Am J Surg 167:618-620, 1994.
63. Klaase JM, Kroon BB, Eggermont AM, et al: A retrospective comparative study evaluating the results of mild hyperthermic versus controlled normothermic perfusion for recurrent melanoma of the extremities. Eur J Cancer 1:58-63, 1995.
64. Cavaliere R, Di Filippo F, Giannarelli D, et al: Hyperthermic antiblastic perfusion in the treatment of local recurrence or "in transit" metastases of limb melanoma. Semin Surg Oncol 8:374-380, 1992.
65. Strauss A, Dritschilo A, Pathausen L, Piro A: Radiation therapy of malignant melanomas: An evaluation of clinically used fractionation schemes. Cancer 47:1262-1266, 1981.
66. Alexander HR, Fraker DL, Bartlett DL: Isolated limb perfusion for malignant melanoma. Semin Surg Oncol 12: 416-428, 1996.